pocketful logo light
pocketful logo light
Alkem Laboratories Ltd logo

Alkem Laboratories Ltd

NSE: ALKEM BSE: 539523

₹5380

(0.30%)

Sun, 27 Sept 2026, 01:16 am

Alkem Laboratories Share Price Live Chart

1 Day

(0.30%)

No Result Found

Summary

  • Market Cap (in Cr)

    65734.45

  • Net Profit (in Cr)

    2216

  • P/B

    4.87

  • Sector P/E

    33.76

  • P/E

    26.94

  • EV/EBITDA

    19.35

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    19.88

  • ROCE

    20.03

  • Debt/Equity

    0.13

  • EPS (TTM)

    203.98

  • Dividend Yield

    0.96

  • Book Value

    1155.87

  • Interest Cover

    21.76

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters51.2051.2051.2053.0455.13
FII10.169.979.489.119.41
DII21.4021.5421.9321.8019.42
Public17.2517.3017.4016.0516.05
Government00000.00

Read More

Technical Analysis

RSI

46.97

MACD

-16.34

50 DMA

5429.57

200 DMA

5495.07

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic6625.336025.835677.675426.335078.174826.834227.33
Fibonacci6025.835796.825655.345426.335197.325055.844826.83
Camarilla5494.365439.415384.455426.335274.555219.595164.64

Pivots Level: Classic

R3

+1199

6625.33

R2

+599.50

6025.83

R1

+251.33

5677.67

5426.33
5426.33
Pivot Point
LTP: 5274

S1

-348.17

5078.17

S2

-599.50

4826.83

S3

-1199

4227.33

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    5307.73

  • 20-EMA

    5306.55

  • 30-EMA

    5329.76

  • 50-EMA

    5371.86

  • 100-EMA

    5420.91

  • 200-EMA

    5435.34

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
28 May 2026board-meetingsAccounts, Quarterly Results, Final Dividend
13 Feb 2026board-meetingsQuarterly Results, Interim Dividend
13 Feb 2026dividend₹43.00 Dividend /Share20 Feb 2026
13 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
08 Jul 2025dividendFinal Dividend - Rs. - 808 Aug 2025
29 May 2025dividend₹8.00 Dividend /Share08 Aug 2025
29 May 2025agm
07 Feb 2025dividend₹37.00 Dividend /Share14 Feb 2025
14 Jan 2025dividendInterim Dividend - Rs. - 3714 Feb 2025
10 Jul 2024dividendFinal Dividend - Rs. - 510 Aug 2024

Read More

Peer Comparison

Alkem Laboratories Ltd logo

Alkem Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Read More

Alkem Laboratories Ltd About

Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical products.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1973

Headquarters

CEO

Basudeo N Singh

Employees

Contact

Website icon

Website

http://www.alkemlabs.com

Email icon

Email

investors@alkem.com ; contact@alkem.com

Phone icon

Phone

91-22-39829999

Location icon

Location

Alkem House SenapatiBapat Marg, Lower Parel, Mumbai, Maharashtra, 400013

Read More

Alkem Laboratories Ltd Company History

YearHistory
2019
  • Alkem crossed the revenue milestone of USD 1 billion.
  • Alkem received the Express Pharma Excellence Award at Pharma CXO Summit 2019.
  • Alkem Laboratories took over an undertaking from Cachet Pharmaceuticals.
2020
  • Alkem launched Favipiravir in India under the brand name 'Alfluenza'.
  • Alkem received the 'Best IT team of the Year' award at the CIO Conclave and Awards 2020.
2021
  • Alkem launched Ibuprofen and Famotidine Tablets in the United States.
  • Alkem launched Perampanel Tablets in India under the brand name 'Perampil'.
  • Alkem launched Brivaracetam in India under the brand name 'Brivasure'.
  • Alkem partnered with Tata Memorial Hospital.
  • Alkem was recognized as one of India's Best Workplaces in Biotechnology & Pharmaceutical Industry for the second consecutive year.
2022
  • Alkem signed a license agreement with Harvard University's Office of Technology Development.
2023
  • The Company entered into a co-development and license agreement with Biosergen AB for the development and commercialization of BSG005.
  • The NCLT approved the Scheme of Amalgamation for the merger of Pharmasofttech Awacs Pvt. Ltd. into Pharmarack Technologies Pvt. Ltd.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
SAMPRADA&NANHAMATI SINGH FAMILY TRUSTbulkSell7554004831.9211 Jun 2025
JAYANTI SINHAbulkSell17000004874.6104 Jun 2025
SAMPRADA&NANHAMATI SINGH FAMILY TRUSTbulkSell641712468021 Feb 2025
UBS PRINCIPAL CAPITAL ASIA LIMITEDbulkSell9895065468.9925 Nov 2024
MORGAN STANLEY ASIA SINGAPORE PTE-ODIblockBuy980005732.1522 Aug 2024
COPTHALL MAURITIUS INVESTMENT LIMITED-NON ODI ACCOUNTblockBuy175005732.1522 Aug 2024
RELIANCE NIPPON LIFE INSURANCE COMPANY LIMITEDblockBuy610005732.1522 Aug 2024
CITIGROUP GLOBAL MARKETS MAURITIUS PRIVATE LTDblockBuy350005732.1522 Aug 2024
BNP PARIBAS ARBITRAGE -NON ODIblockBuy350005732.1522 Aug 2024
KOTAK MAHINDRA MUTUAL FUNDblockBuy610005732.1522 Aug 2024

Read More

Alkem Laboratories Ltd News

Alkem Laboratories CFO steps down

Alkem Laboratories has announced the resignation of its Chief Financial Officer. The development marks a key leadership change at the pharmaceutical company.

24 Sept 2026

companies

Alkem Labs to meet HDFC MF on Oct 7

Alkem Laboratories will hold an in-person one-on-one meeting with HDFC Mutual Fund in Mumbai on October 7, 2026, as per SEBI disclosure.

23 Sept 2026

companies

Alkem Labs launches Neuceno for seizure treatment

Alkem Laboratories has launched Neuceno in India for the treatment of partial-onset seizures in adults, available as a once daily oral dose formulation.

16 Sept 2026

companies

Alkem launches patented hair growth serum

Alkem Laboratories launches Renocia Exo, India's first patented Ginsenoside Exosome-based hair growth serum, targeting follicular health.

08 Sept 2026

companies

Alkem Labs Q1FY27 profit jumps 48% YoY

Alkem Laboratories reported a 48% YoY rise in standalone net profit to ₹432.10 crore for Q1FY27, driven by a 25% surge in revenue to ₹3,444.70 crore.

30 Jul 2026

companies

Read More

Frequently Asked Questions

  • 1.What is the stock price of Alkem Laboratories Ltd?

    As of 27/09/2026 at 6:46 AM, Alkem Laboratories Ltd shares are trading at ₹5380.

  • 2.What is the market cap. of Alkem Laboratories Ltd?

    As of 27/09/2026, the market capitalization of Alkem Laboratories Ltd is ₹63,967.28 crore.

  • 3.When was Alkem Laboratories Ltd founded?

    Alkem Laboratories Ltd was founded in 1973.

  • 4.What are the P/E and P/B ratios of Alkem Laboratories Ltd?

    As of 27/09/2026, Alkem Laboratories Ltd has a P/E ratio of 29.85 and a P/B ratio of 4.87.

  • 5.How can I buy shares of Alkem Laboratories Ltd?

    You can buy shares of Alkem Laboratories Ltd through Pocketful. Simply open a Demat account, complete your KYC, add funds, and place a buy order.

  • 6.What is the shareholding pattern of Alkem Laboratories Ltd?

    As of March,2026, promoters hold 51.20% in Alkem Laboratories Ltd, while FIIs, DIIs and public shareholders hold 10.16%, 21.40% and 17.25%, respectively.

  • 7.Does Alkem Laboratories Ltd pay dividends?

    Yes, Alkem Laboratories Ltd pays dividends to eligible shareholders. The latest dividend announced by the company was ₹₹43.00 Dividend /Share per share.

  • 8.What is the dividend yield of Alkem Laboratories Ltd?

    As of 27 September, 2026, the dividend yield of Alkem Laboratories Ltd stands at 0.96%.

  • 9.What are the latest financial results of Alkem Laboratories Ltd?

    For January,2024, Alkem Laboratories Ltd reported revenue of ₹12,930.00 crore and a net profit of ₹2,165.00 crore.

  • 10.What is the Stock symbol of Alkem Laboratories Ltd?

    ALKEM is the stock symbol of Alkem Laboratories Ltd.

  • 11.Who is the CEO of Alkem Laboratories Ltd?

    The CEO of Alkem Laboratories Ltd is Basudeo N Singh.